|
Gastrointestinal Stromal Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
The diagnosis of GIST is based on histological examination and immunohistochemistry with markers KIT and DOG-1.
|
31387778 |
2019 |
|
Gastrointestinal Stromal Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
Dedifferentiation in GIST is a rare histologic change which may occur de novo or secondary to imatinib therapy and is characterized by abrupt transition of well-differentiated (WD) GIST to a subclonal anaplastic process that shows loss of immunohistochemical marks (CD117, DOG1).
|
31072206 |
2019 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In addition, TMEM16A overexpression-induced cell proliferation was blocked by EGFR/STAT3 inhibitors, and TMEM16A knockdown reduced EGF-induced proliferation and tumorigenesis in breast cancer.
|
31042586 |
2019 |
|
Squamous cell carcinoma of the head and neck
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
TMEM16A overexpression and depletion in SCCHN cell lines caused parallel changes in the ATP7B mRNA levels.
|
31790150 |
2019 |
|
Squamous cell carcinoma of the head and neck
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
TMEM16A is overexpressed in many cancers, including gastrointestinal stromal tumors, gastric cancer, head and neck squamous cell carcinoma (HNSCC), colon cancer, pancreatic ductal adenocarcinoma, and esophageal cancer.
|
30515811 |
2019 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
TMEM16A promoted growth and invasion in lung cancer cells via an EGFR/ MAPK-dependent signaling pathway.
|
30821158 |
2019 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Silencing of ANO1 inhibited proliferation and invasion of ovarian cancer cells.
|
30243029 |
2019 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Knockdown of ANO1 significantly inhibited GC cell migration and invasion in vitro, and loss of ANO1 resulted in inhibition of tumor metastasis in vivo.
|
30871776 |
2019 |
|
Tumor Cell Invasion
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
ANO1 is a direct target of miR-9, and overexpression of miR-9 suppressed both mRNA and protein expression of ANO1 and inhibited cell proliferation, migration, and invasion of HCT116 cells.
|
30803553 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
We will survey TMEM16A contribution in cancer prognosis, the origins of its over-expression in cancer cells, the multiple biological functions and molecular pathways regulated by TMEM16A.
|
31279157 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemically, the tumor cells were positive for p40, p63, cytokeratin 5/6, cytokeratin 7, and cancer antigen 125, but negative for discovered on GIST-1 (DOG1).
|
31177170 |
2019 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A previous study indicated that suppressed Anoctamin-1 expression decreased cancer cell proliferation or migration.
|
29466035 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recently, it has been reported that ANO1 has roles in the progression of human malignant tumors.
|
29416639 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This study will be useful in the development of ANO1 inhibitors for treatment of cancer and other ANO1-related diseases.
|
30347323 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This ANO1 cell-based assay constitutes an important tool to be further used in high-throughput screens and drug discovery of high relevance for CF and cancer.
|
29154949 |
2018 |
|
Cystic Fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This ANO1 cell-based assay constitutes an important tool to be further used in high-throughput screens and drug discovery of high relevance for CF and cancer.
|
29154949 |
2018 |
|
Cystic Fibrosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results suggest that the CF-related environment in the two mouse models did not induce ANO1 overexpression as a compensatory system.
|
29860639 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The results showed that there was a significant difference between the two groups in tumor size (P < 0.001), histological type (P = 0.013), CD34 expression (P < 0.001), and DOG-1 expression (P < 0.001).
|
30445975 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemical investigation of the tumour located in the mesentery showed that the staining for the S-100 protein was strongly positive, while the stainings of SMA, CD34, CD117 and DOG-1 were negative.
|
29375216 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, silencing of ANO1 inhibits growth of PC-3 xenograft tumors in nude mice and induces apoptosis in tumors via upregulation of TNF-α signaling.
|
29899325 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In conclusion, this study demonstrates that ANO1 expression is an indicator of poor prognosis of breast carcinoma patients and suggests that ANO1 might be a therapeutic target for breast carcinoma patients with ANO1-positive tumors and poor prognosis.
|
29416639 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Alterations in the expression of I<sup>-</sup> transporters are associated with tumor development in a cancer-type-dependent manner and, accordingly, NIS, CFTR and ANO1 have been proposed as tumor markers.
|
29437784 |
2018 |
|
Gastrointestinal Stromal Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
Pathologically, diagnosis of a GIST relies on morphology and immunohistochemistry [KIT and/or discovered on gastrointestinal stromal tumor 1 (DOG1) is generally positive].
|
30018476 |
2018 |
|
Gastrointestinal Stromal Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemical examination was performed with primary antibodies to CD34, CD117, SMA, and vimentin, and TMEM16a (DOG-1), the latter was used for the diagnosis of gastrointestinal stromal tumours (GIST) consisting of TCs.
|
29472628 |
2018 |
|
Gastrointestinal Stromal Tumors
|
0.100 |
GeneticVariation
|
group |
BEFREE |
SDH-deficient gastrointestinal stromal tumours (GISTs) show distinctive features, including absent KIT proto-oncogene receptor tyrosine kinase/platelet-derived growth factor receptor A (KIT/PDGFRA) mutations [but positive staining for cKIT and DOG1], virtually exclusive gastric location, lobulated growth, multi-focality, a prognosis not predicted by size and mitotic rate, frequent metastasis to lymph nodes and primary resistance to imatinib therapy.
|
29239034 |
2018 |